Wallbach, Manuel

[["dc.bibliographiccitation.firstpage","829"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Acta Diabetologica"],["dc.bibliographiccitation.lastpage","835"],["dc.bibliographiccitation.volume","52"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Lehnig, Luca-Yves"],["dc.contributor.author","Helms, Hans-Joachim"],["dc.contributor.author","Schroer, Charlotte"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:51:13Z"],["dc.date.available","2018-11-07T09:51:13Z"],["dc.date.issued","2015"],["dc.description.abstract","Aims Sympathetic overactivity is one critical factor associated with the development of arterial hypertension, impaired insulin secretion and resistance. Some antihypertensives exert beneficial effects on glucose metabolism, whereas others lead to an impairment of metabolic state with consecutive weight gain. In resistant hypertension, baroreflex activation therapy (BAT) reduces arterial blood pressure (BP) by inhibition of the sympathetic nervous system. The objective of this study was to evaluate whether BAT influences metabolic state in patients with resistant hypertension. Methods Thirty patients with resistant hypertension (10 with known diabetes mellitus) were prospectively included into this study. Blood pressure, BMI, weight, fasting glucose, insulin, C-peptide, hemoglobin A1c, HOMA-IR, HOMA-beta, ISQuickI, and glucose levels during oral glucose tolerance test were measured at baseline and 6 months after BAT activation. Results Fasting glucose was significantly reduced after 6 months of BAT, whereas mean 2-h glucose levels during oral glucose tolerance test, fasting insulin levels, C-peptide levels, hemoglobin A1c, HOMA-IR, HOMA-beta, ISQuickI, weight, and BMI remained unchanged. Conclusion Despite improvement in fasting glucose, BAT exerts neither sustained additional beneficial effects nor an impairment of metabolic state. Thus, chronic BAT might be an effective interventional method to reduce BP without metabolic disadvantages."],["dc.description.sponsorship","CVRx"],["dc.identifier.doi","10.1007/s00592-014-0679-7"],["dc.identifier.isi","000361346500002"],["dc.identifier.pmid","25539879"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35870"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-5233"],["dc.relation.issn","0940-5429"],["dc.title","Long-term effects of baroreflex activation therapy on glucose metabolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","235"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Clinical Apheresis"],["dc.bibliographiccitation.lastpage","242"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Strauchmann, Julia"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Bramlage, Carsten"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:34:08Z"],["dc.date.available","2018-11-07T09:34:08Z"],["dc.date.issued","2014"],["dc.description.abstract","Lipoprotein apheresis (LA) is believed to exert anti-atherosclerotic effects beyond LDL-cholesterol reduction. We investigated 22 patients undergoing regular LA on a weekly basis (group A) before (AP) and after LA procedure (EP), 15 healthy individuals (group B), and 22 hyperlipoproteinemic patients with concomitant cardiovascular end organ damage treated without LA therapy (group C). Biomarkers of endothelial inflammation (hsCRP), plaque destabilization, and rupture (sVCAM, MMP-9, PAPP-A, ADMA) were quantified. Intergroup comparison revealed a statistically significant lower MMP-9 level in group A (AP and EP) compared with group C (P<0.01), whereas PAPP-A levels were lower in group B compared with group A and C (P=0.04). EP ADMA-levels and EP sVCAM levels in group A were statistically lower compared with group B and C. AP and EP values comparison revealed a significant reduction for hsCRP (mean 41.0 +/- 16.7%, P<0.01), sVCAM (mean 69.6 +/- 14.0%, P<0.01), PAPP-A (mean 88.7 +/- 20.4%, P<0.01), ADMA (mean 69.7 +/- 18.4% P<0.01). In conclusion, we observed a transient decrease in the plasma concentrations of several biomarkers expressed during plaque destabilization and elevated cardiovascular risk after a single LA treatment. J. Clin. Apheresis 29:235-242, 2014. (c) 2013 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/jca.21311"],["dc.identifier.isi","000343831500001"],["dc.identifier.pmid","24281903"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32112"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1098-1101"],["dc.relation.issn","0733-2459"],["dc.title","Lipoprotein Apheresis Reduces Biomarkers of Plaque Destabilization and Cardiovascular Risk"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","786"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","American Journal of Kidney Diseases"],["dc.bibliographiccitation.lastpage","789"],["dc.bibliographiccitation.volume","61"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Groene, Hermann-Josef"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:25:33Z"],["dc.date.available","2018-11-07T09:25:33Z"],["dc.date.issued","2013"],["dc.description.abstract","Recombinant interferon alpha (IFN-alpha) and interferon beta (IFN-alpha) are efficient drugs for clinical use in multiple sclerosis, hepatitis C virus infection, and malignant diseases. We report a case of a 40-year-old woman with relapsing-remitting multiple sclerosis who was treated with interferon beta-1b for several years before being admitted to our department with nephrotic-range proteinuria (protein excretion, 8.3 g/d) and serum albumin level of 2.9 g/dL without any clinical and laboratory change typical for a systemic autoimmune disease. The kidney biopsy led to the diagnosis of immune complex-mediated membranoproliferative glomerulonephritis with immunoglobulin and complement deposits visible by immunohistology, as well as subendothelial deposits and tubuloreticular inclusions evident by electron microscopy. Subsequently replacing interferon beta-1b with glatiramer acetate resulted in partial remission, with proteinuria decreasing to protein excretion of 1.0 g/d 2 months thereafter. The association of a focal mesangiocapillary glomerular change and immunoglobulin-complement deposits with tubuloreticular inclusions suggests lupus nephritis. To our knowledge, this is the first report of an interferon beta-1b-induced immune complex glomerulonephritis characterized by histologic, immunohistologic, and ultrastructural features that resembled lupus nephritis, but that occurred in a patient without evidence of systemic lupus erythematosus. Our review of experimental data and earlier case reports suggests a pathogenic role of recombinant IFN in some autoimmune diseases, especially those with the potency to induce systemic lupus erythematosus-like syndromes. Am J Kidney Dis. 61(5): 786-789. (C) 2013 by the National Kidney Foundation, Inc."],["dc.identifier.doi","10.1053/j.ajkd.2012.11.049"],["dc.identifier.isi","000317276600021"],["dc.identifier.pmid","23375818"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30094"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co-elsevier Inc"],["dc.relation.issn","0272-6386"],["dc.title","Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1625"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Lupus"],["dc.bibliographiccitation.lastpage","1626"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Vasko, Radovan"],["dc.contributor.author","Hoffmann, S."],["dc.contributor.author","Niewold, T. B."],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Korsten, Peter"],["dc.date.accessioned","2018-11-07T10:05:33Z"],["dc.date.available","2018-11-07T10:05:33Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1177/0961203316651746"],["dc.identifier.isi","000387447700015"],["dc.identifier.pmid","27216419"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38918"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1477-0962"],["dc.relation.issn","0961-2033"],["dc.title","Elevated procalcitonin levels in a severe lupus flare without infection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2344"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Journal of Hypertension"],["dc.bibliographiccitation.lastpage","2349"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Beige, Joachim"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Hennig, Gert"],["dc.contributor.author","Hamza, Amir"],["dc.contributor.author","Wendt, Ralph"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Wallbach, Manuel"],["dc.date.accessioned","2018-11-07T09:49:11Z"],["dc.date.available","2018-11-07T09:49:11Z"],["dc.date.issued","2015"],["dc.description.abstract","Background:Resistant arterial hypertension and chronic kidney disease (CKD) are interlinked via sympathetic overactivity. Baroreflex activation therapy (BAT) is a well tolerated therapy, which has been shown to reduce BP in patients with resistant hypertension. The effects of BAT in patients with resistant hypertension and end stage renal disease have not been reported.Method and results:We retrospectively analyzed procedural effectiveness and safety in seven CKD stage 5D patients with resistant hypertension who underwent BAT. One year after activation, office SBP decreased significantly from 19428 to 137 +/- 16mmHg (P<0.01). Ambulatory SBP showed a trend to be decreased from 167 +/- 30 to 137 +/- 24mmHg (P=0.17), whereas the median number of prescribed antihypertensive classes decreased from 5 (4-9) to 3 (1-4) (P=0.01). Intraoperative drop of SBP was -34.3 +/- 34.4mmHg (P=0.04). With respect to adverse events there were minor side-effects (mainly paresthesia and dysphagia) reported in our patients, which occurred according to treatment intensity and modality.Conclusion:BAT is an effective and well tolerated intervention to reduce BP in patients suffering from end-stage renal disease and resistant hypertension. Therefore, BAT might contribute to a reduction of cardiovascular events in those high-risk patients."],["dc.description.sponsorship","CVRx"],["dc.identifier.doi","10.1097/HJH.0000000000000697"],["dc.identifier.isi","000368491800024"],["dc.identifier.pmid","26335429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35456"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1473-5598"],["dc.relation.issn","0263-6352"],["dc.title","Baroreflex activation therapy in patients with end-stage renal failure: proof of concept"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","599"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Rheumatology International"],["dc.bibliographiccitation.lastpage","605"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Froelich, Britta"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Minguet, Joan"],["dc.contributor.author","Grupp, Clemens"],["dc.contributor.author","Deutsch, Cornelia"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Koziolek, Michael"],["dc.date.accessioned","2018-11-07T10:25:49Z"],["dc.date.available","2018-11-07T10:25:49Z"],["dc.date.issued","2017"],["dc.description.abstract","The risk of infection in patients with rheumatic diseases is elevated, but a clear marker to differentiate the cause of the systemic inflammation is missing. We assessed the ability urinary immunoglobulin free light chains (FLCs) to indicate the presence of infection in patients with rheumatic disease. We performed a retrospective analysis of patients with rheumatic disease attending the Georg-August University Hospital in Goettingen, Germany, from January 2011 to December 2013. Subjects were included if they had urine levels of kappa and lambda FLCs available. A reference group of patients without autoimmune disease, but with documented infection, was constructed. A total of 1500 patients had their urinary FLCs quantified during the study period. Of the 382 patients with rheumatic disease, 172 (45%) displayed no systemic inflammation, 162 (42%) had inflammation due to the underlying disease activity, and 48 (13%) had inflammation due to a confirmed infection. Urinary FLC concentrations were much higher in patients with rheumatic diseases and infection (kappa 68.8 +/- 81.8 mg/L, lambda 31.4 +/- 53.5 mg/L) compared to those with inflammation due to rheumatic disease activity (kappa 22.7 +/- 26.3 mg/L, lambda 8.1 +/- 9.1 mg/L, kappa p < 0.001, lambda p = 0.004). Urinary kappa FLCs demonstrated good ability to predict infection, with a sensitivity of 63% and specificity of 84%. Urinary lambda FLCs gave similar values, with a sensitivity of 65% and specificity of 81%. FLCs may be useful for distinguishing inflammation due to rheumatic disease activity from that due to the additional presence of infection. The ability to quantify these proteins in urine provides a simple alternative to the use of blood."],["dc.identifier.doi","10.1007/s00296-017-3666-9"],["dc.identifier.isi","000398591600015"],["dc.identifier.pmid","28214923"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42931"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1437-160X"],["dc.relation.issn","0172-8172"],["dc.title","Urinary free light chains may help to identify infection in patients with elevated systemic inflammation due to rheumatic disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1630"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Hypertension"],["dc.bibliographiccitation.lastpage","1638"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Halbach, Marcel"],["dc.contributor.author","Reuter, Hannes"],["dc.contributor.author","Passauer, Jens"],["dc.contributor.author","Lueders, Stephan"],["dc.contributor.author","Boehning, Enrico"],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T10:11:22Z"],["dc.date.available","2018-11-07T10:11:22Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Both baroreflex activation therapy (BAT) and renal denervation modulate sympathetic activity. The aim of this study was to systematically investigate whether additive modulation of autonomic nervous system by BAT lowers blood pressure (BP) in patients who still suffer from uncontrolled resistant hypertension despite prior renal denervation. Methods: From 2012 to January 2015, patients treated with BAT for uncontrolled resistant hypertension, who prior received renal denervation were consecutively analyzed in four German centers for hypertension. Analyses of office BP, 24-h ambulatory BP, central hemodynamics, parameters of renal function were performed. Results: A total of 28 patients, who underwent renal denervation at least 5 months before and still suffer from uncontrolled BP, were subsequently treated with BAT. The office SBP decreased from 182 +/- 28 to 163 +/- 27 mmHg (P<0.01) with a responder rate of 68% (office SBP reduction >= 10 mmHg) at month 6, whereas the number of prescribed antihypertensive drug classes remained unchanged (6.2 +/- 1.5 vs. 6.0 +/- 1.7, P = 0.30). Serum creatinine, estimated glomerular filtration rate and cystatin C remained stable (P = 1.00, P = 0.41 and P = 0.22, respectively), whereas albuminuria was significantly reduced by a median of -29% (P = 0.02). Central SBP (-15 +/- 24 mmHg, P = 0.047) and end systolic pressure (-14 +/- 20 mmHg, P = 0.03) were significantly reduced. Conclusion: The present data demonstrate that BAT may exert BP-lowering as well as antiproteinuric effects in patients with prior renal denervation. However, precise evaluation of BAT effects in patients with prior renal denervation will need randomized controlled trials using sham procedures."],["dc.description.sponsorship","CVRx"],["dc.identifier.doi","10.1097/HJH.0000000000000949"],["dc.identifier.isi","000379448100028"],["dc.identifier.issn","0263-6352"],["dc.identifier.pmid","27137174"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40027"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1473-5598"],["dc.relation.issn","0263-6352"],["dc.title","Baroreflex activation therapy in patients with prior renal denervation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]